Stable Clonidine Oral Liquid Composition for Room-Temperature Storage

The patent applies parameter changes by optimizing the pH of the liquid composition to a specific range (pH 3.0-5.0) and controlling the concentration of clonidine hydrochloride (10-50 μg/mL). These parameter adjustments significantly improve stability at room temperature while maintaining ease of administration. The pH optimization prevents degradation without requiring refrigeration, resolving the contradiction between liquid form benefits and stability concerns.

The patent introduces stabilizing excipients as intermediaries to protect clonidine from degradation. Specifically, buffers (such as citrate buffer), antioxidants (such as ascorbic acid or sodium metabisulfite), and chelating agents (such as EDTA) are added to the formulation. These intermediary substances act as protective mediators that extend shelf life and maintain potency at room temperature, enabling the liquid form to be both easy to administer and stable.

The patent applies preliminary action by pre-formulating clonidine at standardized concentrations (10, 20, 30, or 50 μg/mL) with optimized stability characteristics. This preliminary formulation work is done during manufacturing, so that when the product reaches the clinic, healthcare providers only need to administer predetermined volumes for precise dosing. This eliminates the need for complex extemporaneous compounding while maintaining dosing precision, as the active ingredient is already prepared at known concentrations with proven stability.

The patent segments the dosing strategy by offering multiple pre-established concentration options (10, 20, 30, 50 μg/mL) to accommodate different clinical needs. This segmentation allows healthcare providers to select the appropriate concentration based on patient requirements without needing to perform complex compounding calculations. Each concentration option is independently optimized and stable, simplifying the overall process while maintaining precision.

The patent fundamentally changes the storage parameter by formulating the liquid composition with pH optimization (pH 3.0-5.0) and incorporating stabilizing excipients that enable room temperature stability. This parameter change eliminates the need for refrigeration (typically required at 2-8°C), allowing the medication to be stored at ambient temperatures (15-30°C) without significant degradation. This resolves the contradiction by maintaining stability while dramatically improving ease of operation and accessibility in settings without refrigeration.

The patent enables a disposable, non-refrigerated formulation that can be stored at room temperature for extended periods (at least 3 months, preferably 6-12 months). This approach replaces the need for expensive refrigeration infrastructure and continuous monitoring. The formulation is designed to be stable under normal storage conditions, making it suitable for use in resource-limited settings, home care, and emergency situations where refrigeration is unavailable or impractical.